COGNITION THERAPEUTICS INC

CGTXNASDAQ

🏆 #3335 by market capEarnings Nov 5US Equity

$1.02▼ $0.03 (−2.86%)

Market closed · at close

1h—

24h▼ 2.9%

7d▼ 4.2%

14d▲ 14.3%

30d▲ 0.0%

1y▼ 6.0%

🏦Market Cap

$91M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

Trading Snapshot

Day Range: $1.01 – $1.04
52-Week Range: $0.55 – $3.83
Volume: $4.48B
Avg Volume: $5.15B
Shares Outstanding: 89.5M
Next Earnings: Oct 7, 2026

Fundamentals Snapshot

Annual Revenue: $14M
Last Q Revenue: $4M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-0.26
Dividend Yield: —

Why Investors Own CGTX

✓High-growth profile — revenue up +51.7% YoY with expanding US Equity exposure.
✓Healthy economics — 68% gross margin and 4% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$14M▲ +58.8% YoY

Gross Margin (TTM)

67.7%▲ +1.4% YoY

Operating Income (TTM)

$4M▲ +58.8% YoY

Free Cash Flow (TTM)

$579,619▲ +58.8% YoY

About COGNITION THERAPEUTICS INC

Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders. Its most advanced experimental therapy is CT1812, which acts as a sigma-2 receptor antagonist. This compound is currently being evaluated in Phase II clinical trials for the management of mild-to-moderate Alzheimer's disease and dementia with Lewy bodies (DLB). Additionally, it has successfully concluded Phase I trials for early-stage Alzheimer's and is undergoing preclinical investigation for dry age-related macular degeneration (AMD). The company's pipeline also includes CT2168, a treatment candidate for synucleinopathies—a category of diseases encompassing DLB and Parkinson's disease—and CT2074, which is in development for dry AMD. Cognition Therapeutics, Inc. was established in 2007 and operates from its headquarters in Purchase, New York.

🦦